Cooccurrence of Two Different Genetic Diseases: A Case of Valproic Acid Hepatotoxicity in Nicolaides–Baraitser Syndrome (SMARCA2 Mutation)—Due to a POLG1-Related Effect?

Abstract

Nicolaides–Baraitser syndrome (NCBRS) is a rare disease caused by a mutation in the SMARCA2 gene. Clinical features include craniofacial dysmorphia and abnormalities of the limbs, as well as intellectual disorder and often epilepsy. Hepatotoxicity is a rare complication of the therapy with valproic acid (VPA) and a mutation of the polymerase γ (POLG) might lead to a higher sensitivity for liver hepatotoxicity. We present a patient with the coincidence of two rare diseases, the NCBRS and additionally a POLG1 mutation in combination with a liver hepatotoxicity. The co-occurrence in children for two different genetic diseases is discussed with the help of literature review.

Keywords

Nicolaides–Baraitser syndrome - SMARCA2 mutation - cooccurrence of two genetic diseases - POLG1-related effect - valproic acid hepatotoxicity

^* Both authors contributed equally to the manuscript.

• References

• 1 Sousa SB, Hennekam RC. ; Nicolaides-Baraitser Syndrome International Consortium. Phenotype and genotype in Nicolaides-Baraitser syndrome. Am J Med Genet C Semin Med Genet 2014; 166C [phone]
• 2 Van Houdt JK, Nowakowska BA, Sousa SB, van Schaik BD, Seuntjens E, Avonce N. , et al. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome. Nature Genetics 2012; 44 (04) 445-9, s1
• 3 Chan SSL, Copeland WC. DNA polymerase gamma and mitochondrial disease: understanding the consequence of POLG mutations. Biochim Biophys Acta 2009; 1787 (05) 312-319
• 4 Wolf NI, Rahman S, Schmitt B. , et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009; 50 (06) 1596-1607
• 5 Stewart JD, Horvath R, Baruffini E. , et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 2010; 52 (05) 1791-1796
• 6 Guillen SS, Meijer M, de Jongh FE. Lethal acute liver failure in a patient treated with sunitinib. BMJ Case Rep 2016; 2016: bcr2015213624
• 7 Lal D, Neubauer BA, Toliat MR. , et al. Increased probability of co-occurrence of two rare diseases in consanguineous families and resolution of a complex phenotype by next generation sequencing. PLoS One 2016; 11 (01) e0146040
• 8 Balci TB, Hartley T, Xi Y. , et al; FORGE Canada Consortium; Care4Rare Canada Consortium. Debunking Occam's razor: Diagnosing multiple genetic diseases in families by whole-exome sequencing. Clin Genet 2017; 92 (03) 281-289
• 9 Yang Y, Muzny DM, Reid JG. , et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013; 369 (16) 1502-1511
• 10 Schmid MM, Freudenmann RW, Keller F. , et al. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 2013; 46 (02) 63-68
• 11 Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000; 34 (05) 630-638
• 12 Striano P, Vari MS, Mazzocchetti C, Verrotti A, Zara F. Management of genetic epilepsies: From empirical treatment to precision medicine. Pharmacol Res 2016; 107: 426-429
• 13 Yagi M, Nakamura T, Okizuka Y. , et al. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatr Int 2010; 52 (05) 744-748
• 14 Inoue K, Suzuki E, Takahashi T. , et al. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. Epilepsy Res 2014; 108 (06) 1046-1051
• 15 Glauser TA. Biomarkers for antiepileptic drug response. Biomarkers Med 2011; 5 (05) 635-641